Request Trial
JarTee / Shutterstock.com
10 April 2025NewsPharmaMuireann Bolger

AstraZeneca fends off diabetes generic, for now

Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Pharma
Novartis scores UK win in high-stakes Entresto fight
14 August 2026   Pressure for generic manufacturers of the blockbuster heart drug Entresto is mounting as the Swiss pharma company secures a win over a challenge to its UK patent protection.
Pharma
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
12 August 2026   Reflecting on decades of patent searching experience, senior scientist on the CAS IP Services team, David Saari, offers insights into the importance of a multidisciplinary approach in today's competitive IP landscape.
Pharma
Lilly mounts defence as generics circle Mounjaro and Zepbound
11 August 2026   A litigation campaign against generic drugmakers, including Sandoz, Hikma, and Amenal, raise the stakes in the fight over two of the world’s most lucrative weight loss and diabetes treatments.


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Why is 2026 already a record year for M&A activity?
17 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Regulation & Industry
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026

More features

Former USPTO acting director takes the helm at C4IP
Europe’s missing biotech bridge: Why IP ownership matters more than capital access
Novartis scores UK win in high-stakes Entresto fight
Invisalign maker secures first China win against clear aligner rival
Holland & Hart adds high-stakes patent litigation team from Ashurst Perkins Coie
The ‘Triple Point’ professional: Why patent success requires science, law, and technology
Exclusive: ‘In the end, I did it my own way’ and became a UPC judge
Lilly mounts defence as generics circle Mounjaro and Zepbound